Neogen Corporation shares remain under pressure as a third law firm, Levi & Korsinsky, announced an investigation into the company for potential federal securities law violations. The probe follows an FDA warning linking the sterile veterinary product HYCOAT to severe infections and at least 20 horse deaths.

Expanding legal investigations

The Law Offices of Frank R. Cruz stated that the investigation concerns possible misrepresentations or omissions by Neogen regarding product safety and regulatory compliance. Investors who purchased Neogen securities and suffered losses are urged to contact the firm to inquire about pursuing claims to recover their losses.

In a parallel development, Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announced it is also investigating claims on behalf of investors. SBS focuses on whether the company issued false or misleading statements or failed to disclose information pertinent to investors. The announcement highlights the expanding legal and financial risks emerging from the FDA’s findings.

Now, Levi & Korsinsky has notified investors of its own investigation. The firm states that eligibility is based on purchase date and documented losses, not on whether shareholders still hold the stock. Investors are encouraged to submit loss information while the investigation is underway.

The Levi & Korsinsky inquiry specifically targets statements made during Neogen's fiscal fourth-quarter earnings call on July 30, 2026. During that call, CEO Mikhael Nassif told investors the Company had "resolved prior supply and quality challenges." The investigation seeks to determine if this assertion was misleading given the subsequent FDA warning, which caused NEOG shares to fall 7.22% in a single trading session. The firm notes that shareholders who have already sold their NEOG shares may still be eligible to participate in potential recovery actions.

Investigation findings

The FDA's inspection and compliance enforcement investigations identified critical failures in manufacturing and quality control processes at Neogen. Federal investigators evaluated more than 95 individual clinical cases following severe adverse events reported in horses across multiple states. Laboratory testing of HYCOAT lot 5A001 confirmed the presence of viable fungal species.

Although marketed as a sterile solution, the contaminated product caused severe health issues, including tissue necrosis, surgical wound dehiscence, systemic sepsis, and painful joint infections resulting in euthanasia. The warning letter explicitly notes that the agency's investigation connected the contamination incident directly to the product defect. The FDA stated the incident involved at least 20 horse deaths, making it the largest number of horse deaths ever associated with a quality defect in an FDA-regulated veterinary medical product and the most deaths of any animal species linked to microbiological contamination of an FDA-regulated product labeled as sterile.

Unsanitary contract manufacturing conditions

A federal inspection of the contract manufacturing facility revealed widespread insanitary production conditions. Regulators documented inadequate environmental cleaning lacking sporicidal agents, unmonitored cleanroom air quality, absent environmental and personnel sampling, and unsterile employee gowning.

The cleanroom, constructed inside a warehouse facility, suffered from structural disrepair and lacked differential pressure monitoring as well as essential airflow smoke studies demonstrating proper air movement.

Critical misbranding and labeling violations

Regulators officially classified HYCOAT as both adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act. The product labeling failed to include necessary warnings regarding frequent off-label joint injections and lacked adequate directions for laypersons managing complex medical conditions like surgical wounds or autograft procedures. Furthermore, packaging omitted required statement language restricting product administration strictly to licensed veterinarians.

Regulatory response and compliance timeline

Following a voluntary recall of HYCOAT lots 4L001, 4L002, and 5A001 on January 28, federal officials emphasized that product distributors retain ultimate legal responsibility for quality oversight. Neogen Vet must submit a comprehensive written response outlining corrective actions within 15 working days to avoid potential legal action or further regulatory enforcement measures.

Financial impact and segment exposure

Neogen Vet products fall within Neogen's Animal Safety segment, which reported $54.5 million in revenue for the third quarter of fiscal 2026. The company's August 21, 2026 proxy statement disclosed a $4.2 million "Other" line item that includes "product recall expenses." Potential fines, litigation costs, and reserves tied to the FDA action have not been quantified.

What the numbers show

The primary metric disclosed is the qualitative magnitude of the impact: the "largest number of deaths in horses" associated with such a defect. While specific numerical counts of affected animals beyond the 95 evaluated cases are not provided, the classification establishes a new negative benchmark for safety violations in this sector. The stock market reaction, with shares down 7.22% to $12.73, reflects investor concern over the severity of the regulatory breach and potential liability.

The initiation of securities fraud investigations by three separate firms adds a layer of legal exposure beyond the immediate regulatory penalties. Notably, the $4.2 million in recall expenses disclosed in the proxy statement represents approximately 7.7% of the Animal Safety segment's quarterly revenue of $54.5 million, highlighting the materiality of the incident relative to the specific business unit affected. The specific focus of the Levi & Korsinsky probe on the July 30, 2026 earnings call creates a direct link between executive communication and market volatility, suggesting that the alleged misrepresentation concerns the timing and completeness of quality control disclosures rather than just the product defect itself.

Neogen (NASDAQ: NEOG) has projected first-quarter sales of $207 million to $209 million, surpassing the consensus analyst estimate of $204.71 million. The guidance signals robust demand for the company’s food safety, animal health, and human health testing solutions ahead of its official earnings release. By exceeding market expectations, Neogen demonstrates resilience in its core markets despite broader economic uncertainties affecting the agricultural and food processing sectors.

The company’s management provided this forward-looking revenue range to update investors on operational performance. The projection covers the first quarter of the fiscal year, offering a clear benchmark against which actual results will be measured when the full financial statements are filed. This proactive disclosure helps reduce uncertainty for shareholders and analysts tracking the biotechnology firm’s quarterly trajectory.

Financial Guidance Overview

The following table outlines the key figures from Neogen’s latest sales projection compared to market expectations:

The midpoint of Neogen’s guidance is approximately $208 million, representing a significant upside relative to the $204.71 million consensus. This positive variance suggests that the company’s recent strategic initiatives and product innovations are resonating well with customers in both domestic and international markets.

What the Numbers Show

The fact that Neogen’s entire projected range sits above the analyst estimate is a notable indicator of underlying business strength. Typically, companies provide guidance that brackets the consensus to manage expectations; however, a floor that exceeds the estimate implies management’s confidence in sustained order flow and pricing power. This divergence highlights effective execution in Neogen’s go-to-market strategies, particularly in high-growth segments such as environmental monitoring and pathogen detection. Investors should monitor whether this top-line momentum translates into proportional margin expansion when the full earnings report is released.